Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer

Angela M. Jarrett, Alay Shah, Meghan J. Bloom, Matthew T. McKenna, David A. Hormuth, Thomas E. Yankeelov, Anna G. Sorace

Research output: Contribution to journalArticle

Abstract

The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by the in vitro data to simulate the tumor cell response to the individual therapies. A collective model merging the two individual drug response models was designed to investigate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations. This collective model shows increased synergy for regimens where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cytotoxic effects of paclitaxel. The synergy derived from the model is found to be in agreement with the combination index, where both indicate a spectrum of additive and synergistic interactions between the two drugs dependent on their dose order. The combined in vitro results and development of a mathematical model of drug synergy has potential to evaluate and improve standard-of-care combination therapies in cancer.

Original languageEnglish (US)
Article number12830
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Paclitaxel
Breast Neoplasms
Pharmaceutical Preparations
Theoretical Models
Therapeutics
Drug Combinations
Standard of Care
Drug Interactions
Neoplasms
Trastuzumab
In Vitro Techniques

ASJC Scopus subject areas

  • General

Cite this

Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer. / Jarrett, Angela M.; Shah, Alay; Bloom, Meghan J.; McKenna, Matthew T.; Hormuth, David A.; Yankeelov, Thomas E.; Sorace, Anna G.

In: Scientific reports, Vol. 9, No. 1, 12830, 01.12.2019.

Research output: Contribution to journalArticle

Jarrett, Angela M. ; Shah, Alay ; Bloom, Meghan J. ; McKenna, Matthew T. ; Hormuth, David A. ; Yankeelov, Thomas E. ; Sorace, Anna G. / Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{1fb7d33dd0f643fd874c6b26b69075a7,
title = "Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer",
abstract = "The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by the in vitro data to simulate the tumor cell response to the individual therapies. A collective model merging the two individual drug response models was designed to investigate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations. This collective model shows increased synergy for regimens where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cytotoxic effects of paclitaxel. The synergy derived from the model is found to be in agreement with the combination index, where both indicate a spectrum of additive and synergistic interactions between the two drugs dependent on their dose order. The combined in vitro results and development of a mathematical model of drug synergy has potential to evaluate and improve standard-of-care combination therapies in cancer.",
author = "Jarrett, {Angela M.} and Alay Shah and Bloom, {Meghan J.} and McKenna, {Matthew T.} and Hormuth, {David A.} and Yankeelov, {Thomas E.} and Sorace, {Anna G.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-49073-5",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer

AU - Jarrett, Angela M.

AU - Shah, Alay

AU - Bloom, Meghan J.

AU - McKenna, Matthew T.

AU - Hormuth, David A.

AU - Yankeelov, Thomas E.

AU - Sorace, Anna G.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by the in vitro data to simulate the tumor cell response to the individual therapies. A collective model merging the two individual drug response models was designed to investigate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations. This collective model shows increased synergy for regimens where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cytotoxic effects of paclitaxel. The synergy derived from the model is found to be in agreement with the combination index, where both indicate a spectrum of additive and synergistic interactions between the two drugs dependent on their dose order. The combined in vitro results and development of a mathematical model of drug synergy has potential to evaluate and improve standard-of-care combination therapies in cancer.

AB - The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by the in vitro data to simulate the tumor cell response to the individual therapies. A collective model merging the two individual drug response models was designed to investigate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations. This collective model shows increased synergy for regimens where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cytotoxic effects of paclitaxel. The synergy derived from the model is found to be in agreement with the combination index, where both indicate a spectrum of additive and synergistic interactions between the two drugs dependent on their dose order. The combined in vitro results and development of a mathematical model of drug synergy has potential to evaluate and improve standard-of-care combination therapies in cancer.

UR - http://www.scopus.com/inward/record.url?scp=85071896974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071896974&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-49073-5

DO - 10.1038/s41598-019-49073-5

M3 - Article

C2 - 31492947

AN - SCOPUS:85071896974

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 12830

ER -